Introduction
The interpretation of the signifi cance of the recovery of Candida from urine specimens is often diffi cult. Candiduria may represent contamination, colonization of the urinary catheter or of the bladder. In people who are infected, all anatomic levels of the urinary tract may be involved. Most cases of candiduria are asymptomatic and treatment is rarely necessary. Candida albicans has been the most 2004 at Akdeniz University Hospital, Antalya, Turkey, were included in the study. Nosocomial infections were defi ned by Centers for Disease Control and Prevention (CDC) criteria used by infection control physicians. Candiduria was considered nosocomial if the infection becomes evident 48 or more hours after admission. The patients were eligible for the study if two consecutive cultures of urine samples were positive for Candida species [3] . Demographic data and underlying diseases of the patients were collected.
Specimens were collected by using midstream urine, straight catheters or from indwelling catheters. The second specimen was obtained after replacing the fi rst catheters in patients with indwelling catheters.
Identifi cation of the isolates was obtained by standard microbiologic procedures and the use of API ID 32C strips (Biomerieux, France). Organisms were identifi ed to the species level by use of the germ tube test, evaluation of morphologic properties on corn meal tween 80 agar and carbohydrate assimilation tests with API ID 32 C strips (Biomerieux, France) [4, 5] . The isolates were stored as suspensions in water until they were used. Each isolate was subcultured at least twice on Sabouraud dextrose agar (SDA) and incubated at 35 ° C prior to testing to ensure purity.
Susceptibilities of the isolates to amphotericin B were determined by the Etest (Biomerieux, France) method according to the manufacturer ' s instructions. Broth microdilution method, specifi ed by Cinical Laboratory and Standards Institute (CLSI; formerly NCCLS) document M27-A3 and M27-S3, were used to evaluate the susceptibilities of the isolates to fl uconazole, voriconazole and caspofungin [6, 7] . Reagent grade powder of fl uconazole, voriconazole (Pfi zer, Inc, New York, USA) and caspofungin (Merck, Australia) were obtained from their respective manufacturers. Stock solutions were prepared in dimethyl sulfoxide (DMSO; voriconazole) or water (fl uconazole and caspofungin). Antifungal susceptibility testing was performed by using RPMI 1640 medium with a fi nal inoculum suspension of 0.5 ϫ 10 3 to 2.5 ϫ 10 3 yeasts per ml. Plates were incubated at 35 ° C and read 24 h after inoculation for caspofungin, and at 48 h for fl uconazole and voriconazole [6, 7] . Minimum inhibitory concentrations (MICs) were determined visually by two separate investigators. The MIC was defi ned as 50% reduction in turbidity compared to that of the growth control.
Interpretive breakpoints established by the CLSI were used for fl uconazole [Susceptible (S), Յ 8 μ g/ml; susceptible dose-dependent (SDD), 16 -32 μ g/ml; Resistant (R), Ն 32 μ g/ml)], voriconazole (S, Յ 1 μ g/ml; SDD, 2 μ g/ml; R, Ն 4 μ g/ml) and caspofungin (S, Յ 2 μ g/ml) [6, 7] . For amphotericin B which has no established interpretive breakpoints, a breakpoint of Յ 1 μ g/ml was used [8] .
Quality control isolates, C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were included in all runs. The study was approved by Akdeniz University Medical Faculty Ethical Committee with B.30.2.AKD.0.01.00.00/ Etik/484 protocol number.
Results
Of the 100 patients with nosocomial candiduria 60 were female. The mean age of the study population was 43.5 Ϯ 26.6 (range 0 -94 years). Underlying diseases included trauma 24%, neurologic disorders 21%, diabetes mellitus 18%, malignancy 13%, pulmonary and heart diseases 11%, urinary system abnormalities 10%, prematurity 8%, organ transplantation 4%, burn 2% and others 7%. The majority of the patients (88%) had indwelling bladder catheters. The most common species isolated was C. albicans 44%, followed by C. tropicalis (20%), C. glabrata (18%), C. krusei (6%), C. famata (5%), C. parapsilosis (4%), C. kefyr (2%) and C. guilliermondii (1%).
MIC ranges, MIC 50 /MIC 90 values of antifungal agents for urinary Candida isolates are shown in Table 1 . A total of nine (9%) of the isolates including fi ve C. krusei and four C. glabrata isolates were susceptible dose dependent (SDD) to fl uconazole, whereas only two C. glabrata and one C. krusei isolates were resistant.
For all Candida isolates, the voriconazole MIC ' s were Յ 0.5 μ g/ml, except for one C. glabrata isolate with a MIC value of 2 μ g/ml for voriconazole. This isolate was also resistant to fl uconazole.
Ninety-four percent of the isolates were susceptible to amphotericin B with MIC ' s lower than 1 μ g/ml. Amphotericin B MIC values of higher than 1 μ g/ml were only found with C. krusei (four isolates) and C. glabrata (two isolates). All isolates were susceptible to caspofungin with MIC values of 0.5 μ g/ml or lower.
Discussion
Recent studies highlight the changing epidemiology of candiduria in hospitalized patients [2,9,10]. In our investigation, C. albicans was the prominent species isolated from urine cultures. However, non-C. albicans Candida species accounted for more than 50% of all isolates in our center which suggests a shift to these species. Kobayashi et al. reported a high incidence of candiduria caused by species other than C. albicans . C. tropicalis (22.2%) was the most common isolate in their study [11] . De Oliviera et al. recovered C. tropicalis from 53% of their 166 candiduria patients [9] . In a case-control study assessing the signifi cance of candiduria in renal transplant recipients, C. glabrata which was recovered from speciments of intermediate susceptible (MIC ϭ 2 μ g/ml). This isolate was also resistant to fl uconazole. Cross resistance between fl uconazole and voriconazole is well described among isolates of C. glabrata . Although C. krusei is intrinsically resistant to fl uconazole, in contrast to C. glabrata , in vitro cross resistance to voriconazole is distinctly uncommon because voriconazole binds much more effectively to the cytochrome P450 isoenzyme target in C. krusei than does fl uconazole [14] . In spite of excellent in vitro activity of voriconazole against Candida spp., no studies of the use of voriconazole for urinary candidiasis have been published to date [3] .
Amphotericin B deoxycolate is another treatment option for Candida urinary tract infections. Amphotericin B deoxycolate bladder irrigation is recommended only for patients whose infection is caused by refractory fl uconazole-resistant organisms [3, 15] . A single intravenous dose of 0.5 -1 mg/kg body weight of amphotericin B deoxycolate has been shown to be effective for candiduria [16] .
In addition to fl uconazole, C. glabrata is innately less susceptible to amphotericin B than most other species of Candida [17] . In our study, two isolates had MICs Ͼ 1 μ g/ ml for amphotericin B. Reduced susceptibility to amphotericin B may be associated with some strains of C. krusei as noted for four isolates in this investigation.
98 (51%) of 191 patiens was the most common isolate [12] . Thus, several published series, along with ours, provide evidence of more resistant strains associated with candiduria in hospitalized patients [2, 9, 10, 12] .
Because of its safety and the pharmacokinetic and pharmacodynamic properties, fl uconazole is preferred for the treatment of Candida urinary tract infections. Other treatment options include fl ucytosine and low-dose amphotericin B. The role of echinocandins and newer azoles that do not achieve measurable concentrations in the urine is not clear [13] .
In our study, high levels of resistance to fl uconazole (MIC Ն 64 μ g/ml) was found in 3% of all species but restricted to isolates of C. glabrata and C. krusei . Sience C. krusei is intrinsically resistant to fl uconazole, it is expected that 100% of strains would be reistant to this antifungal independent of the in vitro susceptibility studies. The fl uconazole susceptibilities of C. glabrata strains vary widely [14] . C. glabrata may be intrinsically resistant to fl uconazole and urinary tract infections caused by this species are the most diffi cult to treat. It is suggested that fl uconazole therapy may be succesful for strains with MIC ' s in the range of 8 -32 μ g/ml and as a result, susceptibility testing should be performed in this situation [3] .
In our study, all Candida spp. were susceptible to voriconazole except one C. glabrata strain which was Flucytosine, which is considered to be as another treatment option in cases of fl uconazole treatment failure is not available in our country.
In conclusion, fl uconazole is still the drug of choice for the treatment of urinary candidiasis in our hospital. It is clear that future studies are needed to defi ne better treatment regimens for those patients who have fl uconazoleresistant Candida urinary tract infections. The changing trends in the epidemiology of candiduria in hospitalized patients, especially with risk factors, should be closely monitored. Species identifi cation and antifungal susceptibility testing may have therapeutic implications.
